Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07599800 APC-101 Neuralgia, Postherpetic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07599800 clinical trial report covering APC-101, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600125457 Regorafenib Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600125457 clinical trial report covering Regorafenib, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608224 Toripalimab HER2 Positive Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07608224 clinical trial report covering Toripalimab, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07605364 Temozolomide Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07605364 clinical trial report covering Temozolomide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07621939 Amulirafusp alfa Immunoglobulin G4-Related Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07621939 clinical trial report covering Amulirafusp alfa, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623187 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07623187 clinical trial report covering Venetoclax, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07626398 Tretinoin Lymphohistiocytosis, Hemophagocytic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07626398 clinical trial report covering Tretinoin, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07627893 Methotrexate Sodium Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07627893 clinical trial report covering Methotrexate Sodium, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07625332 Galantamine Hydrobromide Metabolic Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07625332 clinical trial report covering Galantamine Hydrobromide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07718126 Mazdutide Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718126 clinical trial report covering Mazdutide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07718737 AMT-116(Multitude Therapeutics) metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718737 clinical trial report covering AMT-116(Multitude Therapeutics), Phase 2/3, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07721324 Melatonin Neurolytic Block Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07721324 clinical trial report covering Melatonin, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.